Christopher A Slapak Selected Research

zosuquidar trihydrochloride (LY335979)

5/2004	A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
12/2002	A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher A Slapak Research Topics

Disease

9	Neoplasms (Cancer) 01/2017 - 12/2002
2	Vomiting 01/2015 - 09/2011
2	Nausea 01/2015 - 09/2011
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2015 - 03/2012
2	Fatigue 03/2012 - 09/2011
2	Breast Neoplasms (Breast Cancer) 03/2004 - 01/2002
1	Anemia 01/2017
1	Cardiotoxicity 01/2015
1	Glioblastoma (Glioblastoma Multiforme) 01/2015
1	Hepatocellular Carcinoma (Hepatoma) 01/2015
1	Lung Neoplasms (Lung Cancer) 01/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2015
1	Aspiration Pneumonia 01/2015
1	Disseminated Intravascular Coagulation 06/2013
1	Thrombocytopenia (Thrombopenia) 06/2013
1	Chills 03/2012
1	Fever (Fevers) 09/2011
1	Diarrhea 09/2011
1	Anorexia 09/2011
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2007
1	Disease Progression 05/2007
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2004
1	Leukemia 01/2002

Drug/Important Bio-Agent (IBA)

4	Gemcitabine FDA Link 06/2013 - 06/2004
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 11/2004 - 01/2002
3	Pharmaceutical PreparationsIBA 01/2015 - 01/2002
3	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2004 - 01/2002
2	Monoclonal AntibodiesIBA 01/2017 - 01/2015
2	ocaratuzumabIBA 01/2015 - 03/2012
2	Transaminases (Aminotransferases)IBA 06/2013 - 09/2011
2	LY2334737IBA 06/2013 - 09/2011
2	ProdrugsIBA 06/2013 - 09/2011
2	zosuquidar trihydrochloride (LY335979)IBA 05/2004 - 12/2002
2	Proteins (Proteins, Gene)FDA Link 03/2004 - 01/2002
1	metal transporting protein 1 (ferroportin)IBA 01/2017
1	HepcidinsIBA 01/2017
1	LY2787106IBA 01/2017
1	IronIBA 01/2017
1	LY-2157299IBA 01/2015
1	NivolumabIBA 01/2015
1	BilirubinIBA 06/2013
1	N- ((5- bromo- 2- thienyl)sulfonyl)- 2,4- dichlorobenzamideIBA 11/2011
1	SodiumIBA 11/2011
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2011
1	EnzymesIBA 09/2011
1	Protein Kinase C betaIBA 05/2007
1	enzastaurinIBA 05/2007
1	Docetaxel (Taxotere)FDA Link 11/2004
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 06/2004
1	AntimetabolitesIBA 06/2004
1	LY 475776IBA 03/2004
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2002
1	Etoposide (VP 16)FDA LinkGeneric 01/2002
1	Fluorouracil (Carac)FDA LinkGeneric 01/2002
1	multidrug resistance-associated protein 1IBA 01/2002

Therapy/Procedure

2	Therapeutics 06/2008 - 05/2004
1	Oral Administration 06/2008